LRRK2 and Parkinson disease: These compelling genetic and biochemical data have led to the hypothesis that eliminating aberrant LRRK2 kinase or ROC-GTPase activity might be an effective therapeutic strategy for people with PD who carry LRRK2 missense mutations.